Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andreas Engert

Showing results (31-40 of 379) with videos related to

Pageof 38
Sort By:
European Journal of Haematology|April 23, 2014
Antibodies and antibody-drug conjugates in the treatment of Hodgkin lymphomaDennis A Eichenauer, Andreas Engert
Blood|March 5, 2011
One size for all in Hodgkin lymphoma?Dennis A Eichenauer, Andreas Engert
Acta Haematologica|September 18, 2014
The challenging aspects of managing adolescents and young adults with Hodgkin's lymphomaRon D Jachimowicz, Andreas Engert
Oncology Research and Treatment|October 25, 2017
Checkpoint Inhibition in Hodgkin Lymphoma - a ReviewPaul J Bröckelmann, Andreas Engert
Hematology. American Society of Hematology. Education Program|December 10, 2017
Nodular lymphocyte-predominant Hodgkin lymphoma: a unique disease deserving unique managementDennis A Eichenauer, Andreas Engert
Acta Haematologica|May 30, 2015
What Is the Role of Rituximab in Nodular Lymphocyte-Predominant Hodgkin Lymphoma?Dennis A Eichenauer, Andreas Engert
Nature Reviews. Clinical Oncology|October 6, 2011
Chemotherapy: Hodgkin lymphoma--absence of evidence not evidence of absence!Peter Borchmann, Andreas Engert, Volker Diehl
Expert Opinion on Pharmacotherapy|July 29, 2006
Fludarabine in chronic lymphocytic leukaemiaThomas Elter, Michael Hallek, Andreas Engert
Hematology/Oncology Clinics of North America|October 3, 2007
Hodgkin's lymphoma: new insights in an old disease. PrefaceVolker Diehl, Andreas Engert, Daniel Re
Hematology/Oncology Clinics of North America|October 3, 2007
New strategies for the treatment of advanced-stage Hodgkin's lymphomaVolker Diehl, Andreas Engert, Daniel Re
Pageof 38

Showing results (31-40 of 379) with videos related to

Sort By:
Pageof 38
European Journal of Haematology|April 23, 2014
Antibodies and antibody-drug conjugates in the treatment of Hodgkin lymphomaDennis A Eichenauer, Andreas Engert
Blood|March 5, 2011
One size for all in Hodgkin lymphoma?Dennis A Eichenauer, Andreas Engert
Acta Haematologica|September 18, 2014
The challenging aspects of managing adolescents and young adults with Hodgkin's lymphomaRon D Jachimowicz, Andreas Engert
Oncology Research and Treatment|October 25, 2017
Checkpoint Inhibition in Hodgkin Lymphoma - a ReviewPaul J Bröckelmann, Andreas Engert
Hematology. American Society of Hematology. Education Program|December 10, 2017
Nodular lymphocyte-predominant Hodgkin lymphoma: a unique disease deserving unique managementDennis A Eichenauer, Andreas Engert
Acta Haematologica|May 30, 2015
What Is the Role of Rituximab in Nodular Lymphocyte-Predominant Hodgkin Lymphoma?Dennis A Eichenauer, Andreas Engert
Nature Reviews. Clinical Oncology|October 6, 2011
Chemotherapy: Hodgkin lymphoma--absence of evidence not evidence of absence!Peter Borchmann, Andreas Engert, Volker Diehl
Expert Opinion on Pharmacotherapy|July 29, 2006
Fludarabine in chronic lymphocytic leukaemiaThomas Elter, Michael Hallek, Andreas Engert
Hematology/Oncology Clinics of North America|October 3, 2007
Hodgkin's lymphoma: new insights in an old disease. PrefaceVolker Diehl, Andreas Engert, Daniel Re
Hematology/Oncology Clinics of North America|October 3, 2007
New strategies for the treatment of advanced-stage Hodgkin's lymphomaVolker Diehl, Andreas Engert, Daniel Re
Pageof 38